Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis

Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment

Thu, October 22, 2026 at 6:00 PM UTC 4 min read

Ionis Pharmaceuticals has received FDA orphan drug designation for its treatment targeting a rare form of epilepsy. This designation is significant as it can expedite the development process and provide financial incentives, potentially enhancing the company's market position in the neurology sector. For investors, this news may signal increased growth opportunities and a stronger pipeline, which could positively impact Ionis's stock performance moving forward.

Read full article →

Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?

Wed, October 14, 2026 at 4:43 PM UTC 4 min read

Alnylam Pharmaceuticals recently faced scrutiny after cutting its guidance, raising concerns about its pipeline growth compared to competitors like Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR). This situation is significant for investors as it highlights the competitive landscape in the biotech sector, where pipeline advancements are crucial for maintaining investor confidence and stock performance. Ionis, with its focus on RNA-targeted therapies, may need to demonstrate robust pipeline progress to reassure investors amid these developments.

Read full article →